New Biomarkers of Sepsis with Clinical Relevance

Clinical Relevance of Serum Galactose Deficient IgA1 in Patients with IgA Nephropathy

Journal of Clinical Medicine ◽

10.3390/jcm9113549 ◽

2020 ◽

Vol 9 (11) ◽

pp. 3549

Author(s):

Jin Sug Kim ◽

Hyeon Seok Hwang ◽

Sang Ho Lee ◽

Yang Gyun Kim ◽

Ju-Young Moon ◽

...

Keyword(s):

Iga Nephropathy ◽

Clinical Relevance ◽

Interstitial Fibrosis ◽

Healthy Controls ◽

Ckd Progression ◽

Serum Samples ◽

Tubular Atrophy ◽

Appropriate Treatment ◽

Cox Proportional Hazard Models ◽

New Biomarkers

New biomarkers of IgA nephropathy (IgAN) are needed for non-invasive diagnosis and appropriate treatment. There is emerging evidence that galactose deficient IgA1 (Gd-IgA1) is a pivotal molecule in the pathogenesis of IgAN. However, few studies have investigated the role of Gd-IgA1 as a biomarker in IgAN. In this study, we investigated the clinical relevance of serum Gd-IgA1 levels in patients with IgAN. Two hundred and thirty biopsy-proven IgAN patients, 74 disease controls (patients with non-IgAN nephropathy), and 15 healthy controls were enrolled in this study. Levels of serum Gd-IgA1 were measured using an ELISA kit in serum samples obtained the day of renal biopsy. We compared levels of serum Gd-IgA1 according to the type of glomerular disease and analyzed the association between Gd-IgA1 levels and clinical and pathological parameters in patients with IgAN. We then divided IgAN patients into two groups according to Gd-IgA1 level and investigated the predictive value of Gd-IgA1 for progression of chronic kidney disease (CKD). Serum Gd-IgA1 levels were significantly higher in IgAN patients than disease controls and healthy controls. In patients with IgAN, serum Gd-IA1 levels were significantly correlated with estimated glomerular filtration rate, serum IgA level, and tubular atrophy/interstitial fibrosis. CKD progression was more frequent in IgAN patients with higher serum Gd-IgA1 levels than in those with lower serum Gd-IgA1 levels. Cox proportional hazard models showed that high GdIgA1 level was an independent risk factor for CKD progression after adjusting for several confounders. Our results suggest that serum Gd-IgA1 level is a useful diagnostic and prognostic marker in IgAN patients. Further studies with a larger sample size and longer follow-up duration are needed.

Download Full-text

Biomarkers for Diagnosing and Staging of Fabry Disease

Current Medicinal Chemistry ◽

10.2174/0929867324666170616102112 ◽

2018 ◽

Vol 25 (13) ◽

pp. 1530-1537 ◽

Cited By ~ 6

Author(s):

Johannes Kramer ◽

Frank Weidemann

Keyword(s):

Fabry Disease ◽

Clinical Relevance ◽

Cardiac Involvement ◽

Lysosomal Storage ◽

Timely Initiation ◽

Disease Biomarkers ◽

Long Time ◽

New Biomarkers ◽

Deficient Activity

Background: Fabry disease is an X-linked lysosomal storage disorder caused by deficient activity of α -galactosidase A which leads to progressive intracellular accumulation of globotriaosylceramide in tissues and organs including heart, kidney, vascular endothelium, the nervous system, the eyes and the skin. Cardiac involvement is common, leads to fatal complications and is mainly responsible for reduced life expectancy in Fabry disease. The exact staging of disease progression and timely initiation of treatment is essential in Fabry disease. Therefore, it is essential to use the possibilities of specific biomarkers for early detection of organ involvement or early diagnosis. Methods: By the use of Pubmed all relevant papers for biomarkers in Fabry disease were screened. The quality of retrieved papers was appraised using standard tools. Finally, 70 peer reviewed paper were included. Results: In the past biomarkers for Fabry disease biomarkers did not have clinical relevance. Nowadays, a lot of research is focusing on identification of new biomarkers and their clinical relevance. Only two biomarkers reached clinical applicability. Lyso-GB3 for identification of atypical FD variants and hsTNT for identification of cardiac involvement, which should indicate further diagnostics. Treatment response to ERT can be monitored by lyso-GB3 but data for long-time outcome are missing. A lot of GB3-related analogs are identified in urine and plasma, some of which might play an important role for managing Fabry disease in future. Conclusion: In conclusion, we suggest to measure lyso-GB3 and hsTNT at least once a year. The routine measurement of these two biomarkers will help now for the staging of every individual patient and in addition, will help for a better general understanding of Fabry disease.

Download Full-text

Selected Abstracts of Recent Research in Stuttering

Perspectives on Fluency and Fluency Disorders ◽

10.1044/ffd9.1.5 ◽

1999 ◽

Vol 9 (1) ◽

pp. 5-6

Author(s):

Carrie Bain ◽

Nan Bernstein Ratner

Keyword(s):

Large Volume ◽

Clinical Relevance

Due to the large volume of fluency-related publications since the last column, we have chosen to highlight those articles of highest potential clinical relevance.

Download Full-text